INCREASED WORK LOSS DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS COMPARED TO MATCHED HEALTHY CONTROLS

Birgit Blomjous1, Marike ter Wee2, Alexandre Voskuyl2, Hanneke de Vries2, Irene E.M. Buttink1, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; 3Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; 4Rheumatology and Immunology Center, Amsterdam, Netherlands; 5Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Background: Women with systemic lupus erythematosus (SLE) might be more vulnerable to reduce or stop working during pregnancy because of the increased risk of pregnancy complications compared to the general population. However, no data on work loss during pregnancy and return to work after maternity leave in patients with SLE are available.

Objectives: We aimed to investigate several work outcomes during and after pregnancy in women with SLE compared to matched pregnant controls.

Methods: A case-control study on employment was performed in pregnant women with SLE and matched controls. Matching criteria were age, year of delivery, and number of living infants. Employment was defined as having >8 hours/week of paid work before conception. Four work outcomes were investigated: interruption of work for >1 week during pregnancy, complete cessation of work for >1 week until delivery, reduction in working hours during pregnancy, and the time in weeks to return to work after maternity leave.

Results: A total of 142 women were included (21 SLE patients, 21 controls). Mean SELENA-SLEDAI before pregnancy in SLE patients was 2.6 (SD 2.3). Interruption of work for >1 week or completely stop working during pregnancy occurred in 10 SLE women, compared to 2 controls (OR=8.6, 95% CI [1.6-46.8], p=0.012). From the women who completely stopped working until delivery (n=8), 7 women had SLE (OR=1.4, 95% CI [0.07-28.1], p=0.826). In addition, in women continuing working, reduction of working hours occurred in 5 women with SLE versus 3 controls (OR=1.9, 95% CI [0.4-9.1], p=0.436).

Conclusion: Pregnant women with SLE more frequently completely stop working or reduce working hours compared to matched healthy controls. These findings warrant improved counseling of these women and attention of health care providers, including company doctors.

Disclosure of Interests: Birgit Blomjous Speakers bureau: UCB Pharma

REFERENCES

ACKNOWLEDGEMENT
Study/editorial support by Fishawack Indicia Ltd, UK funded by GSK.

18F-FDG-PET/CT, 11C-METHIONINE-PET/CT AND MULTI-PARAMETRIC MRI IN THE EVALUATION OF DISEASE ACTIVITY AND GLAND FUNCTION IN PRIMARY SJÖGREN’S SYNDROME

Michele Bombardieri1, Coziana Curtin2, Michalis Kostapanos3, Elisa Astori1, Anwar Tappuni1, Natasha Jordan1, Saleem Azeem5, Teresa Fuller6, Paul Galette6, Marius de Groot6, Neel Patel6, Andre Maurik5, Rhea Kershaw5, Calum Gray5, Ruth Tarzi5

Background: Saliva and tear flow rates and minor salivary gland biopsy are typically used to assess gland function and disease activity in primary Sjögren’s syndrome (pSS); however, these have limitations. Imaging methods can directly visualize and generate quantitative values in individual glands. 18F-FDG-PET/CT (18F-FDG) measures glucose metabolism, a potential surrogate for inflammation; 11C-methionine-PET/CT (11C-met) is an amino acid PET tracer that assesses protein synthesis, a potential surrogate for gland synthetic function.

Objectives: Explore the potential of molecular imaging and multi-parametric MRI to characterize and quantify pSS disease manifestations.

Methods: In this pilot imaging study (203818), patients with pSS diagnosed per AECG criteria, with a EULAR Sjögren’s syndrome disease activity index score ≥5, and basal salivary flow ≥0.0 mL/min or stimulated salivary flow rate ≥0.05 mL/min, underwent 18F-FDG and 11C-met and dynamic contrast-enhanced and diffusion-weighted MRI, followed by minor salivary gland biopsy for histological analysis. Age- and sex-matched healthy volunteers (HV) underwent MRI and 11C-met. HV pSS mean differences (m-diff; 95% confidence intervals [CI]) were calculated and Pearson’s correlation coefficients (r) estimated. Peak PET standard uptake values (SUVEpeak) were used in the correlations and SUVmax values were recorded. All methods were compared with routine clinical and laboratory tests.

Results: 12 patients had MRI, 11C-FDG and 11C-met; while HV (n=12) had MRI (n=12) and 11C-met (n=8). A lower 11C-met SUVEpeak was seen in the parotid (m-diff: 1.4 g/mL [0.4, 2.3]) and submandibular (m-diff: 2.0 g/mL [0.9, 3.2]) glands in pSS versus HV, as was a trend for lower lacrimal gland uptake (m-diff: 0.5 g/mL [-0.2, 1.3]) in patients with pSS. On structural MRI, the fat fraction (mean%) was higher in pSS vs HV in the submandibular glands (m-diff: -14.8 [CI: -29.3, -0.4]), with similar trends observed in the parotid glands (m-diff: [24.3, 1.9]). There was a negative correlation between 11C-met uptake and fat fraction (r: -0.7 [-0.9, -0.4]) in the combined parotid glands. There was positive correlation between 11C-met uptake and stimulated salivary flow (r: 0.5 [0.03, 0.6]) and negative correlation for stimulated salivary flow and fat fraction (r: -0.5 [-0.8, -0.1]) in the parotid glands. Similar correlations were also seen in the submandibular glands. There was negative correlation between the global lymphoid aggregation score on minor salivary gland biopsy and the combined salivary gland fat fraction (r: -0.7 [-0.9, -0.2]). Parotid gland SUVmax 18F-FDG uptake was higher than historical control values (mean: 1.9 g/mL [SD: 0.5]) in some patients (pSS mean SUVmax: 2.8 g/mL [SD: 0.8, range 1.7–4.6]), with positive correlation between 18F-FDG and 11C-met uptake (r: 0.7 [0.2, 0.9]) in the combined salivary glands.

Conclusion: Imaging showed clear differences between pSS and HV and correlated with clinical endpoints. Low 11C-met uptake and high fat fraction on MRI may indicate poor residual gland function, while high 18F-FDG and stable 11C-met uptake may define a subpopulation that responds well to anti-inflammatory therapies.

ACKNOWLEDGEMENT
Study/editorial support by Fishawack Indicia Ltd, UK funded by GSK.


Background: Clinical manifestations of systemic lupus erythematosus (SLE) and infections sometimes are difficult to distinguish. In clinical practice low complement and anti(d)DNA levels are used to assess lupus activity but...